Gena Selected for Barclay’s Eagle Labs Female Founder Accelerator
We’re excited to announce that Gena’s co-founder and Chief Scientific Officer, Upasana Bedi Chanana, has been accepted onto the prestigious Barclays Eagle Labs Female Founder Accelerator! This milestone not only highlights our commitment to revolutionising cancer care but also underscores the importance of empowering female entrepreneurs in the digital healthcare space.
About the Barclays Eagle Labs Female Founder Accelerator
Barclays Eagle Labs is dedicated to supporting the next generation of entrepreneurs, and its Female Founder Accelerator is a flagship programme aimed at closing the gender gap in entrepreneurship. Barclays Eagle Labs and AccelerateHER have specifically designed the programme to address the unique challenges faced by women in business, this program provides:
- Tailored Workshops: Sessions that focus on building essential skills, from scaling operations to securing funding.
- Mentorship from Industry Experts: Access to a network of experienced professionals who guide startups on their growth journey.
- Peer-to-Peer Networking: A community of like-minded female founders, fostering collaboration and mutual support.
- Resources for Success: Tools and insights to help participants thrive in competitive markets.
Learn more about the program here.
What Joining Barclays Female Founder Accelerator This Means for Gena
Joining the Barclays Female Founder Accelerator is a pivotal moment for Gena as we continue to innovate in the digital healthcare sector. Here’s why this program is a game-changer for us:
- Empowering Female Leadership: This program is a testament to the growing recognition of women-led startups like Gena that are making waves in healthcare innovation.
- Enhanced Strategic Focus: With tailored workshops and expert mentorship, we’ll refine our strategies to scale effectively and deliver even more impact to cancer patients and their carers.
- Building a Stronger Network: Being part of a vibrant community of female entrepreneurs gives us opportunities for collaboration, learning, and mutual growth.
- Access to Growth Opportunities: From funding guidance to partnership opportunities, the accelerator equips us with the tools we need to expand Gena’s reach and capabilities.
Gena’s Mission: Transforming Cancer Care
At Gena, we’re building a platform designed to empower cancer patients and their caregivers with personalised resources, tools, and support. Our mission is deeply rooted in addressing the challenges of navigating cancer journeys with empathy, innovation, and actionable solutions.
The Barclays Female Founder Accelerator aligns perfectly with our goals, enabling us to:
- Develop more impactful features for our platform.
- Expand our resources to serve diverse communities better.
- Foster a culture of innovation driven by strong female leadership.
A Thank You to Our Supporters
We extend heartfelt thanks to our team, community, and partners who have been instrumental in helping us reach this milestone. Your belief in our mission inspires us to keep pushing boundaries and creating meaningful solutions.
What’s Next?
Over the coming months, we’ll be participating in immersive workshops, networking events, and mentorship sessions as part of the Barclays Female Founder Accelerator. This program will further equip us to scale our impact and continue our journey of transforming cancer care.
We’ll be sharing updates and insights from the program, so stay connected to follow our progress. Together, we’re shaping the future of digital healthcare.
Want to learn more about Gena or support our mission? Reach out to us or subscribe to our updates for the latest news.
Download our cancer glossary now.
Cancer explained simply.
Skomer founded Gena after his mother passed away from Glioblastoma, a devastating brain cancer. As her caregiver and a cancer researcher, he witnessed the severe limitations in treating rare cancers.
Thus, Gena was born. Gena’s mission is to give cancer patients access to all available personalised treatment pathways. Informing better treatment decisions. Empowering cancer patients.
Skomer previously worked in the tech sector, responsible for building scaling teams. He completed his MSc at UCL’s School of Engineering in 2022, having written his dissertation on the applications of genomics within the health sector and beyond.
